>
Switch to:

Opiant Pharmaceuticals Current Ratio

: 10.46 (As of Jun. 2021)
View and export this data going back to 2007. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Opiant Pharmaceuticals's current ratio for the quarter that ended in Jun. 2021 was 10.46.

Opiant Pharmaceuticals has a current ratio of 10.46. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Opiant Pharmaceuticals's Current Ratio or its related term are showing as below:

NAS:OPNT' s Current Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.62   Max: 10.46
Current: 10.46

0.01
10.46

During the past 13 years, Opiant Pharmaceuticals's highest Current Ratio was 10.46. The lowest was 0.01. And the median was 0.62.

NAS:OPNT's Current Ratio is ranked lower than
99.99% of the 317 Companies
in the Biotechnology industry.

( Industry Median: 4.36 vs. NAS:OPNT: 10.46 )

Opiant Pharmaceuticals Current Ratio Historical Data

The historical data trend for Opiant Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20
Current Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 2.59 2.99 7.00 9.21

Opiant Pharmaceuticals Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.58 6.06 9.21 9.12 10.46

Competitive Comparison

For the Biotechnology subindustry, Opiant Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Opiant Pharmaceuticals Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Current Ratio falls into.



Opiant Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Opiant Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2020

Current Ratio (A: Dec. 2020 )=Total Current Assets (A: Dec. 2020 )/Total Current Liabilities (A: Dec. 2020 )
=59.099/6.42
=9.21

Opiant Pharmaceuticals's Current Ratio for the quarter that ended in Jun. 2021 is calculated as

Current Ratio (Q: Jun. 2021 )=Total Current Assets (Q: Jun. 2021 )/Total Current Liabilities (Q: Jun. 2021 )
=60.518/5.784
=10.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opiant Pharmaceuticals  (NAS:OPNT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Opiant Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals Business Description

Opiant Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
233 Wilshire Blvd, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
Thomas Thomas T. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Sinclair Michael director, 10 percent owner 86 GLOUCESTER PLACE LONDON XX W1U6HP
Collard Craig A director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Daly Richard J director 355 ALHAMBRA CIRCLE SUITE 1500 CORAL GABLES FL 33134
Macdougall Ann L. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Silver Gabrielle Alison director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Gorman Brian other: General Counsel 233 WILSHIRE BLVD SUITE 280 SANTA MONICA CA 90401
Skolnick Phil officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC. 433 HACKENSACK AVENUE HACKENSACK NJ 07601
Crystal Roger director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE 10TH FL. NEW YORK NY 10022
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC. 201 SANTA MONICA BLVD., SUITE 500 SANTA MONICA CA 90401
Thompson Rahsaan other: General Counsel 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Mottiwala Aziz officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Wolf Geoffrey 10 percent owner 445 PARK AVENUE 10TH FL. NEW YORK NY 10022
Pollack Kevin director, officer: See Remarks 150 RAINVILLE ROAD TARPON SPRINGS FL 34689
Meuse Joseph J director, 10 percent owner 211 FALMOUTH STREET WARRENTON VA 20186

Opiant Pharmaceuticals Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)